How to select cancer patients for immunotherapy
Open Access
- 6 January 2021
- journal article
- editorial
- Published by Elsevier BV in EBioMedicine
- Vol. 63, 103184
- https://doi.org/10.1016/j.ebiom.2020.103184
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysisEBioMedicine, 2020
- Frequency of discordance in programmed death-ligand 1 (PD-L1) expression between primary tumors and paired distant metastases in advanced cancers: a systematic review and meta-analysisActa Oncologica, 2020
- Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trialsTherapeutic Advances in Medical Oncology, 2020
- Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer PatientsClinical Chemistry, 2019
- Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysisBMJ, 2018